Dyne founder heads up new RNA-editing startup


The founder of muscular dystrophy company Dyne Therapeutics Inc. is heading up a new venture, this time focused on the burgeoning field of RNA medicines.

Previous RTP biotech inks potential $400M deal with Bayer subsidiary
Next Podcast: Moffitt Cancer Center CEO sees future immunotherapy success in selective collaboration